1.87
0.54%
0.01
Cellectis Adr stock is traded at $1.87, with a volume of 29,798.
It is up +0.54% in the last 24 hours and up +3.89% over the past month.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
See More
Previous Close:
$1.86
Open:
$1.86
24h Volume:
29,798
Relative Volume:
0.61
Market Cap:
$187.18M
Revenue:
$5.15M
Net Income/Loss:
$-65.35M
P/E Ratio:
-0.9397
EPS:
-1.99
Net Cash Flow:
$-20.85M
1W Performance:
+0.00%
1M Performance:
+3.89%
6M Performance:
-35.96%
1Y Performance:
-33.69%
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CLLS | 1.87 | 187.18M | 5.15M | -65.35M | -20.85M | -1.99 |
VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-17-23 | Initiated | Bryan Garnier | Buy |
May-18-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-06-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
Nov-08-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Oct-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
Apr-28-21 | Downgrade | Guggenheim | Buy → Neutral |
Mar-16-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
May-12-20 | Initiated | Robert W. Baird | Outperform |
Mar-06-20 | Downgrade | Goldman | Neutral → Sell |
Oct-30-19 | Resumed | Guggenheim | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
May-24-19 | Resumed | Citigroup | Neutral |
Mar-14-19 | Initiated | William Blair | Outperform |
Dec-19-18 | Initiated | Goldman | Neutral |
Jul-16-18 | Initiated | Barclays | Overweight |
Mar-16-18 | Initiated | Guggenheim | Neutral |
Sep-05-17 | Downgrade | SunTrust | Buy → Hold |
Sep-05-17 | Reiterated | Wells Fargo | Outperform |
Mar-02-17 | Initiated | Instinet | Buy |
Feb-28-17 | Initiated | Wells Fargo | Outperform |
Apr-05-16 | Initiated | Ladenburg Thalmann | Buy |
Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
Jul-20-15 | Initiated | BofA/Merrill | Buy |
Apr-20-15 | Initiated | Jefferies | Buy |
Apr-20-15 | Initiated | Piper Jaffray | Overweight |
View All
Cellectis Adr Stock (CLLS) Latest News
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
Cellectis's SWOT analysis: gene-editing firm's stock faces pivotal year ahead - Investing.com
Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com
Earnings call: Cellectis reports robust cash reserves, new R&D initiatives - Investing.com
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
Cellectis earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com South Africa
Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com
Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
A year in review: Cellectis ADR (CLLS)’s performance in the last year - US Post News
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Market Insights: Cellectis ADR (CLLS)'s Notable Drop of -5.84, Closing at 2.02 – DWinneX - The Dwinnex
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - The Globe and Mail
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results - The Globe and Mail
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results - Investing.com India
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results By Investing.com - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower - MSN
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com India
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca - Investing.com India
European Equities Traded in the US as American Depositary Receipts Fall Again in Tuesday Trading - MSN
CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions - AstraZeneca
There's a Lot of Upside For Emerging Gene-Editing Companies - The Globe and Mail
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com
Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News
Cellectis Completes Sale of $47 million through its ATM program - The Globe and Mail
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - The Globe and Mail
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
30 Stocks Moving In Wednesday's Pre-Market SessionAdtran Holdings (NASDAQ:ADTN), Adient (NYSE:ADNT) - Benzinga
7 Gene Editing Companies Investors Should Watch - Nanalyze
25 Stocks Moving In Tuesday's Pre-Market SessionBioCryst Pharma (NASDAQ:BCRX) - Benzinga
25 Stocks Moving In Monday's Pre-Market SessionAltisource Portfolio (NASDAQ:ASPS) - Benzinga
Top 10 Luxury Car Brands In The World - Insider Monkey
Cellectis (CLLS) Stock Price, News & AnalysisNASDAQ - MarketBeat
Morning Market GainersCellectis (NASDAQ:CLLS) - Benzinga
New Strong Buy Stocks for October 27th - Nasdaq
Cellectis Adr Stock (CLLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):